✦ LIBER ✦

The radiosensitising effects of Iressa (ZD 1839), an EGFR tyrosine kinase inhibitor, on related bladder cancer cell lines in vitro

✍ Scribed by S. Maddineni; V. Sangar; J. Hendry; C. Betts; K. O'Flynn; N. Clarke

Book ID: 118644330
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 222 KB
Volume: 2
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(03)80177-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Differential radiosensitisation by ZD183

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines

✍ Maddineni, S B; Sangar, V K; Hendry, J H; Margison, G P; Clarke, N W 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 141 KB

The EGFR-selective tyrosine kinase inhib

The EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is an effective inhibitor of tamoxifen-resistant breast cancer growth

✍ J. Gee; I. Hutcheson; J. Knowlden; D. Barrow; M. Harper; H. Jones; A. Wakeling; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 192 KB

871 poster Combination of the EGFR-tyros

871 poster Combination of the EGFR-tyrosine kinase inhibitor ZD1839 (gefitinib, Iressa) and ionizing irradiation in glioma cell lines

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 245 KB

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

ZD1839 (Iressa), a novel epidermal growt

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

✍ Neil G. Anderson; Tawhid Ahmad; Kai Chan; Richard Dobson; Nigel J. Bundred 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 192 KB 👁 1 views

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro

ZD1839 (Gefitinib, ‘Iressa’), an epiderm

ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma

✍ Fuminori Teraishi; Shunsuke Kagawa; Takanori Watanabe; Yasuhisa Tango; Takeshi K 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 444 KB